- Home
- INCY vs RGA Comparison
INCY vs RGA Comparison
Compare INCY & RGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INCY | RGA |
|---|---|---|
| Founded | 1991 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 12.3B |
| IPO Year | 1993 | 1993 |
Fundamental Metrics
Financial Performance| Metric | INCY | RGA |
|---|---|---|
| Price | $102.46 | $193.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 10 |
| Target Price | $90.71 | ★ $239.89 |
| AVG Volume (30 Days) | ★ 2.0M | 361.6K |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 1.93% |
| EPS Growth | ★ 3878.02 | 18.96 |
| EPS | 5.90 | ★ 12.98 |
| Revenue | $4,813,105,000.00 | ★ $22,304,000,000.00 |
| Revenue This Year | $19.59 | $7.97 |
| Revenue Next Year | $10.88 | $10.36 |
| P/E Ratio | $17.37 | ★ $14.85 |
| Revenue Growth | ★ 18.09 | 1.97 |
| 52 Week Low | $53.56 | $159.25 |
| 52 Week High | $109.28 | $232.97 |
Technical Indicators
Market Signals| Indicator | INCY | RGA |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 56.87 |
| Support Level | $100.55 | $188.29 |
| Resistance Level | $107.61 | $194.50 |
| Average True Range (ATR) | 2.94 | 4.17 |
| MACD | -0.98 | 0.63 |
| Stochastic Oscillator | 45.19 | 87.85 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.